ARVINAS INC. - COMMON STOCK

Arvinas to Participate in Upcoming Investor Conferences

29 8 2024 07:00:48 提供 Nasdaq GlobeNewswire

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

30 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

24 6 2024 16:37:13 提供 Nasdaq GlobeNewswire

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

21 6 2024 07:00:51 提供 Nasdaq GlobeNewswire

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

17 6 2024 07:00:03 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

03 6 2024 16:30:00 提供 Nasdaq GlobeNewswire

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

23 5 2024 17:00:15 提供 Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

16 5 2024 06:00:45 提供 Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

09 5 2024 16:42:04 提供 Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

07 5 2024 07:00:11 提供 Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

02 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

24 4 2024 16:30:38 提供 Nasdaq GlobeNewswire

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

11 4 2024 07:00:49 提供 Nasdaq GlobeNewswire

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

18 3 2024 16:40:46 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 3 2024 07:00:04 提供 Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 2 2024 07:00:07 提供 Nasdaq GlobeNewswire

Arvinas Announces Chief Financial Officer Transition

20 2 2024 16:05:04 提供 Nasdaq GlobeNewswire

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

20 2 2024 07:00:44 提供 Nasdaq GlobeNewswire

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

06 2 2024 06:45:00 提供 Nasdaq GlobeNewswire

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

01 2 2024 16:30:20 提供 Nasdaq GlobeNewswire